Clearer Thinking with Spencer Greenberg Genomics and Health Outcomes (with Noor Siddiqui)
Jul 4, 2021
Noor Siddiqui, Founder and CEO of Orchid and a former AI researcher at Stanford, dives into the explosion of genomic advancements. She explains how genetic testing can empower prospective parents to assess health risks for their future children, emphasizing the ethical implications. Noor contrasts Orchid's comprehensive services with other genetic testing companies, explores the role of 'junk DNA', and discusses the complexities of gene editing technologies like CRISPR. Plus, she addresses the moral obligations parents face regarding genetic risks.
AI Snips
Chapters
Transcript
Episode notes
Designer Babies
- Advancements like IVG could facilitate designer babies by enabling selection for desired traits beyond disease mitigation.
- This raises ethical questions about genetic engineering and its potential implications.
Yao Ming
- The Chinese government reportedly arranged for Yao Ming's parents, both tall athletes, to have a child.
- This demonstrates government interest in influencing genetics for specific outcomes.
Orchid vs. 23andMe
- Orchid's testing differs from 23andMe by focusing on reproductive decisions, analyzing the whole genome, and providing genetic counseling.
- Orchid also offers actionable mitigation strategies based on results.